3 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisHemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosisActive, not recruitingPhase 32026-10-01NCT04562389
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathyRecruitingPhase 32026-09-11NCT07059000
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaCytopenia, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood platelet disease, bone marrow disorder, hematologic disorder, primary myelofibrosis, thrombocytopeniaRecruitingPhase 22026-02-12NCT05980806